Mumbai: Cipla Limited has announced that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in Hauppauge, Long Island, New York, USA, as No Action Indicated (NAI).

In a regulatory filing, Cipla informed the stock exchanges that it had received communication from the USFDA regarding the outcome of the inspection conducted at the InvaGen manufacturing facility between October 19 and October 22, 2026.

The inspection was previously disclosed by the company through an intimation dated October 23, 2026. Following the inspection, the USFDA communicated its classification on November 17, 2026, assigning the facility a No Action Indicated (NAI) status.

The NAI classification indicates that the USFDA did not identify any conditions warranting regulatory or enforcement action based on the inspection findings.

InvaGen Pharmaceuticals Inc. is a wholly owned subsidiary of Cipla Limited, a Mumbai-headquartered pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products across various therapeutic categories.

Also Read: Cipla, China's SBP Group Ink Exclusive Deal to Develop, Commercialise Cancer Drug TQB2102 in India, South Africa

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .